​

Halozyme Therapeutics Ownership | Who Owns Halozyme Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Halozyme Therapeutics Ownership Summary

Halozyme Therapeutics is owned by 97.29% institutional investors, 1.06% insiders, and 1.64% retail investors. Blackrock is the largest institutional shareholder, holding 13.88% of HALO shares. iShares Core S&P Mid-Cap ETF is the top mutual fund, with 3.35% of its assets in Halozyme Therapeutics shares.

HALO Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockHalozyme Therapeutics97.29%1.06%1.64%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.80%11.85%52.35%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock17.62M13.88%$922.58M
Blackrock funding, inc. /de13.27M11.07%$857.32M
Vanguard group11.57M9.87%$778.45M
State street4.94M4.12%$319.13M
Invesco4.01M3.35%$259.33M
Boston partners2.68M2.24%$173.43M
Morgan stanley2.56M2.14%$165.60M
William blair investment management2.53M2.11%$163.25M
Geode capital management2.51M2.09%$161.98M
Snyder capital management l p2.32M1.94%$150.14M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Panoramic capital116.42K5.28%$7.52M
Koa wealth management93.82K4.38%$6.06M
Cutter capital management, lp120.00K3.33%$7.66M
Snyder capital management l p2.32M2.91%$150.14M
Mizuho markets americas1.32M2.34%$85.54M
2xideas91.66K2.32%$5.92M
South street advisors232.94K2.18%$15.05M
Future fund95.12K2.16%$6.15M
Bernzott capital advisors68.28K2.11%$4.41M
Steamboat capital partners109.74K1.76%$7.09M

Top Buyers

HolderShares% AssetsChange
Boston partners2.68M0.18%2.20M
Norges bank1.90M0.01%1.90M
Two sigma investments, lp1.58M0.08%867.59K
Vanguard fiduciary trust747.36K0.01%747.36K
William blair investment management2.53M0.54%683.02K

Top Sellers

HolderShares% AssetsChange
Dld asset management, lp---30.00M
Macquarie group---1.55M
Arrowstreet capital, limited partnership1.92M0.07%-1.30M
Frontier capital management---1.27M
Millennium management471.28K0.01%-992.66K

New Positions

HolderShares% AssetsChangeValue
Norges bank1.90M0.01%1.90M$128.20M
Vanguard fiduciary trust747.36K0.01%747.36K$48.30M
Axa investment managers130.56K0.03%130.56K$9.58M
Cutter capital management, lp120.00K3.33%120.00K$7.66M
Vanguard asset management108.50K0.01%108.50K$7.01M

Sold Out

HolderChange
Total investment management-1.00
Nemes rush group-2.00
Harbor investment advisory-4.00
Ross\johnson & associates-4.00
Dv trading-4.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 20266310.64%116,597,570-5.33%970.88%3230.94%206-8.85%
Dec 31, 2025371-39.58%62,451,323-58.49%530.35%186-37.79%135-43.04%
Sep 30, 2025351-37.21%58,910,289-54.67%480.42%159-40.67%146-31.78%
Jun 30, 2025552-1.08%129,712,8686.64%1061.10%263-16.51%21229.27%
Mar 31, 202515-97.10%5,085,362-95.89%40.04%6-97.75%4-97.75%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
iShares Core S&P Mid-Cap ETF3.97M3.35%-2.00K
Vanguard US Total Market Shares ETF4.03M3.27%3.36K
Vanguard Total Stock Mkt Idx Inv3.76M3.17%21.04K
iShares Russell 2000 ETF3.13M2.54%-
Vanguard Small Cap Index2.72M2.29%-5.47K
Aviva Investors GlConvtAbsRet I USD Acc2.74M2.16%2.74M
SPDR® S&P Biotech ETF2.18M1.86%4.86K
Delaware Small Cap Core I1.74M1.37%-10.77K
Vanguard Small Cap Growth Index Inv1.53M1.29%2.16K
JHancock Disciplined Value Mid Cap I1.43M1.20%258.64K

Recent Insider Transactions

DateNameRoleActivityValue
Jun 03, 2026Torley Helen PRESIDENT AND CEOSell$137.47K
Jun 03, 2026Torley Helen PRESIDENT AND CEOSell$101.51K
Jun 03, 2026Torley Helen PRESIDENT AND CEOSell$26.55K
Jun 01, 2026Torley Helen PRESIDENT AND CEOSell$106.88K
Jun 01, 2026Torley Helen PRESIDENT AND CEOSell$875.59K

Insider Transactions Trends

DateBuySell
2027 Q1--
2026 Q1--
2025 Q4-13
2025 Q3-27
2025 Q2-7

HALO Ownership FAQ

Who Owns Halozyme Therapeutics?

Halozyme Therapeutics shareholders are primarily institutional investors at 97.29%, followed by 1.06% insiders and 1.65% retail investors. The average institutional ownership in Halozyme Therapeutics's industry, Biotech Stocks , is 35.80%, which Halozyme Therapeutics exceeds.

Who owns the most shares of Halozyme Therapeutics?

Halozyme Therapeutics’s largest shareholders are Blackrock (17.62M shares, 13.88%), Blackrock funding, inc. /de (13.27M shares, 11.07%), and Vanguard group (11.57M shares, 9.87%). Together, they hold 34.82% of Halozyme Therapeutics’s total shares outstanding.

Does Blackrock own Halozyme Therapeutics?

Yes, BlackRock owns 13.88% of Halozyme Therapeutics, totaling 17.62M shares as of Jun 2024. This represents 0.02% of BlackRock's total assets, with a market value of 922.58M$. In the last quarter, BlackRock decreased its holdings by -622K shares, a -3.41% change.

Who is Halozyme Therapeutics’s biggest shareholder by percentage of total assets invested?

Panoramic capital is Halozyme Therapeutics’s biggest shareholder by percentage of total assets invested, with 5.28% of its assets in 116.42K Halozyme Therapeutics shares, valued at 7.52M$.

Who is the top mutual fund holder of Halozyme Therapeutics shares?

iShares Core S&P Mid-Cap ETF is the top mutual fund holder of Halozyme Therapeutics shares, with 3.35% of its total shares outstanding invested in 3.97M Halozyme Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools